- •Clobazam dose should be reduced 2–4 weeks after addition of cenobamate.
- •There may be a synergistic interaction between cenobamate and clobazam.
- •Addition of small clobazam dose can be considered in patients not seizure-free on cenobamate.
Report insights into the pharmacokinetic and pharmacodynamic interaction between cenobamate (CNB) and clobazam (CLB), derived from data in patients enrolled at our center in a global multicenter open-label safety study of CNB.
Materials & Methods
Patients in this study either took CLB at baseline (n = 6) or had CLB added after CNB titration to maximal dose (n = 5) in addition to other antiseizure medications. Clobazam was always administered as a single bedtime dose. Random serum concentrations of CLB and N-desmethylclobazam (N-CLB) were obtained.
Baseline daily CLB doses were 20–50 mg. Sedation began in the six baseline CLB patients at CNB doses of 25–100 mg. The N-CLB/ CLB ratio increased proportionally to the CNB dose. CLB was stopped in all six patients, five of whom were ≥50% responders. Seizure control deteriorated after stopping CLB, with only one remaining responder. Clobazam was restarted at 5 mg/d in five of the six patients. At the last follow-up, four of these patients were continuing CLB; two were seizure-free and 2 were ≥50% responders. Among the five patients that added 5 mg/d CLB de novo, three were responders. All patients were still on CNB at the end of the study.
Data suggest starting CLB dose reduction at CNB doses of 25–100 mg/d. Due to possible synergy, the addition of low-dose CLB could be considered in patients with incomplete response to CNB.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Epilepsy & Behavior
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology.Epilepsia. 2017; 58: 512-521
- Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology.Epilepsia. 2017; 58: 522-530
- Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study.Epilepsia. 2020; 61: 1099-1108
- Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open-label study.Epilepsia. 2021; 62: 3005-3015
- Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications.Epilepsia. 2021; 62: 3016-3028
- Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group.Epilepsy Res. 1997; 26: 423-432
- The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction.Epilepsia. 1999; 40: 1141-1146
- Comparative efficacy of combination drug therapy in refractory epilepsy.Neurology. 2012; 78: 62-68
- Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials.Epilepsia. 2020; 61: 1082-1089
- Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.Acta Neurol Scand. 2021; 143: 154-163
- Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis.Epilepsia. 2020; 61: 1090-1098
- Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam.Epilepsy Res. 2020; 160106263
- Pharmacodynamic synergism contributes to the antiseizure action of cannabidiol and clobazam.Exp Neurol. 2023; 360114286
- A retrospective non-interventional study evaluating the pharmacokinetic interactions between cenobamate and clobazam.Epilepsia. 2023;
Published online: April 08, 2023
Accepted: February 21, 2023
Received in revised form: February 21, 2023
Received: January 9, 2023
© 2023 Elsevier Inc. All rights reserved.